Studying a new targeted drug for advanced GIST after other treatments fail
Part of Cancer, Digestive system clinical trials.
This study tests a new pill called velzatinib for people with GIST that has spread or can't be removed by surgery, after other treatments have stopped working. It may help shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have GIST that has spread to other parts of the body or cannot be removed by surgery.
- You have already tried imatinib, sunitinib, regorafenib, and pimitespib and they either stopped working or caused severe side effects.
- You have had genetic testing showing a change in the KIT or PDGFRA genes.
- You do not have untreated or active brain metastases.
- You do not have serious, uncontrolled heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets people with GIST who are already benefiting from velzatinib in another trial continue taking it. The goal is to keep providing the drug while researchers gather more information on its long-term effects.
This program offers early access to an investigational drug called velzatinib for people with advanced GIST that has a KIT mutation. It is for patients who have run out of standard treatment options and cannot join other clinical trials.
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests a drug called lenvatinib for people with advanced GIST that has not responded to three previous treatments. It may offer a new option if standard therapies have stopped working or caused severe side effects.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.